Active	Status	Sponsor type	Region	Phase	Filter
7 Active 4 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kennecke, Hagen
NEO-RT, NCT06205485: Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer	Recruiting	3	250	Canada, US	Leucovorin, Oxaliplatin, Fluoruracil, Capecitabine, Radiation	Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, NRG Oncology, SWOG Cancer Research Network	Rectal Cancer	01/30	06/30
NCT04668976: A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma	Recruiting	2	100	US	Medtronic pump and Codman catheter, Floxuridine (FUDR), Gemcitabine, Oxaliplatin, Irinotecan (CPT-11), Fluorouracil, Anti-EGFR (Panitumumab or Cetuximab)	Benaroya Research Institute, Virginia Mason Hospital/Medical Center	Colorectal Cancer, Cholangiocarcinoma	12/23	12/24
NEO, NCT03259035: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer	Completed	2	58	Canada, US	Folfox Protocol, Capox	Canadian Cancer Trials Group	Rectal Cancer	04/24	04/24
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer	Active, not recruiting	2	234	Europe, US, RoW	Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care	Agenus Inc.	Metastatic Colorectal Cancer	02/25	07/25
SHORT, NCT04417699: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer	Completed	2	13	US	TAS 102, Tipiracil hydrochloride, Oxaliplatin, Eloxatin	Providence Health & Services, Taiho Oncology	Rectal Cancer	12/23	02/24
NCT05249114: Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors	Active, not recruiting	1	6	US	Cabozantinib, Cabometyx, Lu-177, Lutathera	Providence Health & Services, Exelixis, Advanced Accelerator Applications SA	Neuroendocrine Tumors	12/24	12/26
SALUS, NCT03691064: Post-Authorization Long-Term Safety Study of LUTATHERA	Active, not recruiting	N/A	1014	Europe, US	LUTATHERA, Lu 177 dotatate	Advanced Accelerator Applications	Neuroendocrine Tumors	06/28	06/28